EGFR antisense DNA

N/A

Report date: 2022/01/14 13:23:58
NME

Base Information

Drug NameEGFR antisense DNA
Drug Alias NameN/A
ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Oligonucleotide > Oligonucleotide antisense
Mechanisms of ActionEpidermal growth factor receptor erbB1 antagonists
TargetsEpidermal growth factor receptor erbB1
Therapy Area/IndicationsHead and Neck Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusPending (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesUniversity Of PittsburghNational Cancer Institute
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesUniversity Of PittsburghNational Cancer Institute
Active IndicationsN/A
Inactive IndicationsHead and Neck Neoplasms

Other Information

ATC CodeN/A
Related LinksN/A